IL3RA and leukemia: By contrast, in the MOLM-13 model, 80–100% of the mice treated with 10 mg/kg IL3RA-ADC survived without signs of leukemia until day 123, when the study was terminated (Figure 2B), while all mice treated with the isotype control ADC were sacrificed due to signs of disease by day 67 after tumor cell inoculation.